Alterations in Peripheral Metabolites as Key Actors in Alzheimer's Disease

Curr Alzheimer Res. 2023;20(6):379-393. doi: 10.2174/1567205020666230825091147.

Abstract

Growing evidence supports that Alzheimer's disease (AD) could be regarded as a metabolic disease, accompanying central and peripheral metabolic disturbance. Nowadays, exploring novel and potentially alternative hallmarks for AD is needed. Peripheral metabolites based on blood and gut may provide new biochemical insights about disease mechanisms. These metabolites can influence brain energy homeostasis, maintain gut mucosal integrity, and regulate the host immune system, which may further play a key role in modulating the cognitive function and behavior of AD. Recently, metabolomics has been used to identify key AD-related metabolic changes and define metabolic changes during AD disease trajectory. This review aims to summarize the key blood- and microbial-derived metabolites that are altered in AD and identify the potential metabolic biomarkers of AD, which will provide future targets for precision therapeutic modulation.

Keywords: Alzheimer’s disease; Metabolomics; blood; gut microbiota; homeostasis.; metabolites.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / metabolism
  • Brain / metabolism
  • Cognition
  • Humans
  • Metabolomics